Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Real-World Treatment Patterns and Outcomes of Proteasome Inhibitor (PI: Bortezomib [V], Carfilzomib [K], or Ixazomib [I])-Lenalidomide/Dexamethasone (Rd)-Triplets By Prior Lenalidomide-Exposure in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Engaged in Routine Care in the United States (US)

Larysa Sanchez, MD, Dasha Cherepanov, Dorothy Romanus, RPh, PhD, Aditya Raju, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-136597

Published: 2020

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Sharanya Murty, PhD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 2167.

https://doi.org/10.1182/blood.V130.Suppl_1.2167.2167

Published: 2017

Journal Articles

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Ajai Chari, MD, Dorothy Romanus, Katarina Luptakova, MD, Aditya Raju, MS, Eileen Farrelly, MPH, Marlo Blazer, PharmD, Tomas Skacel, MD, Parameswaran Hari, MD MRCP, MS

Blood (2017) 130 (Supplement 1): 1818.

https://doi.org/10.1182/blood.V130.Suppl_1.1818.1818

Published: 2017

Journal Articles

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Marlo Blazer, PharmD, BCOP, Brian Seal, RPh, MBA, PhD, Huai-Che Shih, PhD, Augustina Ogbonnaya, MPH, Michael Eaddy, PharmD, PhD, Bruce J Dezube, MD

Blood (2016) 128 (22): 5540.

https://doi.org/10.1182/blood.V128.22.5540.5540

Published: 2016

Journal Articles

Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Anna O. D'Souza, B.Pharm, PhD, Dinara Makenbaeva, MD MBA, Eileen Farrelly, MPH, Pamela Landsman-Blumberg, MPH, DrPH, Bjorn Bolinder, MSc,MBA

Blood (2015) 126 (23): 4478.

https://doi.org/10.1182/blood.V126.23.4478.4478

Published: 2015

NARROW

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Email alerts

ASH Publications

American Society of Hematology

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Duration of Therapy (DOT) and Time to Next Therapy (TTNT) of Bortezomib, Carfilzomib and Ixazomib Combinations with Lenalidomide/Dexamethasone (VRd, KRd, IRd) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Clinical Practice in the United States Vs Clinical Trial Experience

Treatment Patterns and Outcomes Among Patients with Higher-Risk Myelodysplastic Syndromes Treated in a Real-World Setting: Electronic Medical Record-Based Data

Evaluation of Cardiovascular Disease Risk in Chronic Myelogenous Leukemia Patients Using Electronic Medical Records from Community-Based Oncology Practices in the United States

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only